These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8579057)

  • 1. Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.
    Tisdale JF; Figg WD; Reed E; McCall NA; Alkins BR; Horne MK
    Am J Hematol; 1996 Feb; 51(2):152-7. PubMed ID: 8579057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
    Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC;
    Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
    Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
    Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suramin-induced skin reactions.
    O'Donnell BP; Dawson NA; Weiss RB; Myers CE; James WD
    Arch Dermatol; 1992 Jan; 128(1):75-9. PubMed ID: 1531404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
    Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
    Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer].
    Wichterich K; Tebbe B; Handke A; Dieckmann KP; Gollnick H
    Hautarzt; 1994 Feb; 45(2):84-7. PubMed ID: 8150636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
    Chi KN; Gleave ME; Klasa R; Murray N; Bryce C; Lopes de Menezes DE; D'Aloisio S; Tolcher AW
    Clin Cancer Res; 2001 Dec; 7(12):3920-7. PubMed ID: 11751483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
    Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.
    Lawrence JB; Conover CA; Haddad TC; Ingle JN; Reid JM; Ames MM; Suman VJ; Marks RS; Erlichman C; Hartmann LC
    Clin Cancer Res; 1997 Oct; 3(10):1713-20. PubMed ID: 9815555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-mediated thrombocytopenia secondary to suramin.
    Seidman AD; Schwartz M; Reich L; Scher HI
    Cancer; 1993 Feb; 71(3):851-4. PubMed ID: 8431868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
    Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
    Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin-induced immune mediated thrombocytopenia.
    Beg MS; Komrokji RS; Ahmed K; Safa MM
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):925-7. PubMed ID: 18204841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
    Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
    J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of platelet aggregation induced by HLA-related antibodies.
    Brandt JT; Julius CJ; Osborne JM; Anderson CL
    Thromb Haemost; 1996 Nov; 76(5):774-9. PubMed ID: 8950789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotype antibodies.
    Selleng K; Warkentin TE; Sheppard JA; Greinacher A
    Transfusion; 2009 Sep; 49(9):1812-8. PubMed ID: 19497062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation.
    LaRocca RV; Cooper MR; Uhrich M; Danesi R; Walther MM; Linehan WM; Myers CE
    Urol Clin North Am; 1991 Feb; 18(1):123-9. PubMed ID: 1992566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heparin-induced thrombopenia: significance and difficulties of precise identification of the immunologic mechanism].
    Samama MM; Elalamy I; Lecrubier C; Potevin F; Horellou MH; Conard J
    Bull Acad Natl Med; 1998; 182(7):1517-33; discussion 1534-6. PubMed ID: 9916345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentosan-induced thrombocytopenia: support for an immune complex mechanism.
    Goad KE; Horne MK; Gralnick HR
    Br J Haematol; 1994 Dec; 88(4):803-8. PubMed ID: 7529541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
    Piscitelli SC; Forrest A; Lush RM; Ryan N; Whitfield LR; Figg WD
    Pharmacotherapy; 1997; 17(3):431-7. PubMed ID: 9165547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.